ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
This site is part of the Siconnects Division of Sciinov Group
This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.
ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
28 Apr, 2025
Asahi Kasei Bioprocess America, Inc. (AKBA), a leading provider of advanced filtration and fluid management solutions for the biopharmaceutical industry, has received the Best Technologies Innovation Award at INTERPHEX 2025. The award recognizes the company’s innovative THESYS® Cleavage & Deprotection (C&D) and Tangential Flow Filtration (TFF) unit—a pioneering system that is reshaping efficiency standards in oligonucleotide (oligo) manufacturing.
Oligonucleotides, short synthetic strands of DNA or RNA, are essential in the development of cutting-edge therapies for conditions such as genetic disorders and cancer. AKBA distinguished itself by introducing a novel system that merges two traditionally separate unit operations—C&D and ultrafiltration/diafiltration (UF/DF)—into a single, integrated and automated process. This advancement significantly enhances manufacturing efficiency, supporting biomanufacturers seeking to boost oligo production and scale up operations.
Asahi Kasei Bioprocess has long been at the forefront of oligonucleotide manufacturing innovation, and the THESYS unit exemplifies our dedication to enabling the next generation of therapeutics, said Chris Rombach, President of Asahi Kasei Bioprocess America. This award affirms our ongoing commitment to driving progress in bioprocessing and delivering transformative value to our customers.
INTERPHEX is a leading industry event showcasing technological advancements in pharmaceutical and biotechnology manufacturing. The 2025 edition highlighted disruptive technologies with the potential to transform industry practices, with AKBA’s THESYS C&D/TFF unit standing out for its impact.
The THESYS unit not only consolidates equipment and conserves valuable lab space, but also supports rapid, sequential processing ahead of purification. It comes equipped with advanced control features, an ergonomic design, and an integrated tank system—further reinforcing its role as a next-generation solution for oligonucleotide production.